KPP
RXRX icon

Kings Path Partners’s Recursion Pharmaceuticals RXRX Stock Holding History

Kings Path Partners’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,000
Closed -$10.1K – 335
2025
Q2 		$10.1K Hold
2,000
– – ﹤0.01% 220
2025
Q1 		$10.6K Hold
2,000
– – 0.01% 213
2024
Q4 		$13.5K Buy
2,000
+1,000
+100% +$6.72K 0.01% 231
2024
Q3 		$6.59K Buy
+1,000
New +$7.17K ﹤0.01% 251

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Kings Path Partners's RXRX Position: Q3 2025 in Review

Kings Path Partners sold out of Recursion Pharmaceuticals (RXRX) in Q3 2025, closing a stake of 2,000 shares — an estimated $10.1K sold.

Kings Path Partners first reported a position in RXRX in Q3 2024 and held it in 4 quarters. The position peaked at $13.5K in Q4 2024. 322 funds tracked by Wall St. Rank hold RXRX as of Q3 2025.

  • Kings Path Partners reported no remaining Recursion Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Kings Path Partners sold 2,000 Recursion Pharmaceuticals shares in Q3 2025, an estimated $10.1K.
  • Kings Path Partners first reported a position in Recursion Pharmaceuticals in Q3 2024 and held it in 4 quarters.
  • Kings Path Partners's Recursion Pharmaceuticals position peaked at $13.5K in Q4 2024.
  • 322 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2025.

Based on Kings Path Partners's 13F filing for Q3 2025, filed 13 Jul 2026.